Patent Case Watch

Patent opinions from the Eastern District of Texas and the U.S. Court of Appeals for the Federal Circuit

Fed. Cir.

Amgen Inc. v. Sandoz Inc., No. 18-1551 (Fed. Cir. May 8, 2019)

Affirmed
Non-Infringement Claim Construction Summary Judgment
Court
U.S. Court of Appeals for the Federal Circuit
Case No.
No. 18-1551
Also Docketed
No. 18-1552 (consolidated; same document)
Decided
May 8, 2019
Judge
Lourie, J.
Document
Precedential Opinion
Length
16 pages

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Amgen Inc. and Amgen Manufacturing Ltd. (collec- tively, “Amgen”) appeal from two decisions of the United States District Court for the Northern District of California in two patent infringement actions brought by Amgen un- der the Biologics Price Competition and Innovation Act (“BPCIA”), 42 U.S.C. § 262 (2012). The court construed claims of U.S. Patents 6,162,427 (t he “’427 patent”) and 8,940,878 (the “’878 patent”) , Amgen Inc. v. Sandoz Inc. , No. 14-CV-04741-RS, 2016 WL 4137563 (N.D. Cal. Aug.

Download Opinion (PDF)

Source: govinfo.gov USCOURTS collection · retrieved July 23, 2026 · Report an error